clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-75-80clinvest-532Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWВозможность и перспективы применения препарата умифеновир у пациентов с COVID-19Current and future use of umifenovir in patients with COVID-19https://orcid.org/0000-0002-6753-8572КиселёвЮ. Ю.KiselevYu. Yu.

Киселёв Юрий Юрьевич – PhD, доцент факультета наук о здоровье OsloMet

Осло

Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet

Oslo

https://orcid.org/0000-0002-5251-5319ЗагородниковаК. А.ZagorodnikovaK. A.

Загородникова Ксения Александровна – к. м. н., PhD, зав. отделом клинической фармакологии. SPIN-код: 4669-2059

Санкт-Петербург

Zagorodnikova Ksenia A. – Candidate of Medical Sciences, PhD, Head of the Department of Clinical Pharmacology. SPIN code: 4669-2059

St. Petersburg

https://orcid.org/0000-0002-2295-7167ИващенкоД. В.IvashchenkoD. V.

Иващенко Дмитрий Владимирович – к. м. н., с. н. с. отдела персонализированной медицины НИИ молекулярной и персонализированной медицины. SPIN-код: 9435-7794

Москва

Ivashchenko Dmitriy V. – Candidate of Medical Sciences of the Department of personalized medicine of the research Institute of molecular and personalized medicine. SPIN code: 9435-7794

Moscow

https://orcid.org/0000-0001-7903-2977КрюковА. В.KrykovA. V.

Крюков Александр Викторович – к. м. н., ассистент кафедры онкологии и паллиативной медицины. SPIN-код: 1568-4967

Москва

Kryukov Alexander V. – Candidate of Medical Sciences, assistant of the Department of Oncology and palliative medicine of the Department of Clinical Pharmacology and Therapy. SPIN code: 1568-4967

Moscow

https://orcid.org/0000-0002-2970-3442СычёвИ. Н.SychevI. N.

Сычёв Игорь Николаевич – к. м. н., доцент кафедры клинической фармакологии и терапии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Россия, Москва; зав. отделением клинической фармакологии ГБУЗ ГКБ им. С.С. Юдина ДЗМ. SPIN-код: 7282-6014

Москва

Sychev Igor N. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy, Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Russia, Moscow; Head Department of clinical pharmacology State budgetary institution of health care of the city of Moscow «city clinical hospital named after S. S. Yudin of the department of health care of the city of Moscow». SPIN code: 7282-6014

Moscow

https://orcid.org/0000-0002-6636-3950МатвеевА. С.MatveevA. S.

Матвеев Александр Витальевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8518-1320

Москва

Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320

Moscow

https://orcid.org/0000-0002-9307-4994МирзаевК. Б.MirzaevK. B.

Мирзаев Карин Бадавиевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8308-7599

Москва

Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599

Moscow

https://orcid.org/0000-0003-0623-7263ОтделеновВ. А.OtdelenovV. A.

Отделенов Виталий Александрович – доцент кафедры клинической фармакологии и терапии. SPIN-код: 8357-5770

Москва

Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770

Moscow

https://orcid.org/0000-0003-4810-2295ЦветовВ. М.TsvetovV. M.

Цветов Виталий Михайлович – к. м. н., врач — клинический фармаколог. SPIN-код: 3202-7659

Челябинск

Tsvetov Vitaly M. – Candidate of Medical Sciences, Doctor — Clinical Pharmacologist. SPIN code: 3202-7659

Chelyabinsk

https://orcid.org/0000-0002-2431-3429ДмитриевА. В.DmitrievA. V.

Дмитриев Александр Викторович – к. б. н., с. н. с. отдела биоинформатики

Москва

Dmitriev Alexander V. – Candidate of Biology Sciences, Department of bioinformatics

Moscow

https://orcid.org/0000-0001-7937-2621ПоройковВ. В.PoroikovV. V.

Поройков Владимир Васильевич – к. ф-м. н., д. б. н., профессор, чл.-корр. РАН, руководитель отдела биоинформатики, заведующий лабораторией. SPIN-код: 8272-7797

Москва

Poroikov Vladimir V. – Candidate of physical and mathematical Sciences, Doctor of Biology Sciences, Professor, Corresponding Member RAS, Head of the bioinformatics Department, Head of the laboratory. SPIN code: 8272-7797

Moscow

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comУниверситет Осло МетрополитенНорвегияOslo Metropolitan UniversityNorwayФГБУ «Национальный медицинский исследовательский центр имени В. А. Алмазова» Минздрава РоссииРоссияNational Medical Research Center named after V.A. Almazov of the Ministry of Health of RussiaRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ГБУЗ ГКБ им. С.С. Юдина ДЗМРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia; State budgetary institution of health care of the Clinical hospital named after S. S. Yudin of the Moscow city department of health careRussian FederationФГБУ «Федеральный центр сердечно-сосудистой хирургии» Минздрава РоссииРоссияFederal Center for Cardiovascular Surgery of the Ministry of Health of RussiaRussian FederationФГБНУ «Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича»РоссияInstitute of Biomedical ChemistryRussian Federation20202810202004SФармаCOVID7580Copyright © Киселёв Ю.Ю., Загородникова К.А., Иващенко Д.В., Крюков А.В., Сычёв И.Н., Матвеев А.С., Мирзаев К.Б., Отделенов В.А., Цветов В.М., Дмитриев А.В., Поройков В.В., Сычёв Д.А., 20202020Киселёв Ю.Ю., Загородникова К.А., Иващенко Д.В., Крюков А.В., Сычёв И.Н., Матвеев А.С., Мирзаев К.Б., Отделенов В.А., Цветов В.М., Дмитриев А.В., Поройков В.В., Сычёв Д.А.Kiselev Y.Y., Zagorodnikova K.A., Ivashchenko D.V., Krykov A.V., Sychev I.N., Matveev A.S., Mirzaev K.B., Otdelenov V.A., Tsvetov V.M., Dmitriev A.V., Poroikov V.V., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/532

На момент публикации обзора основания для применения умифеновира при COVID-19 носят в основном теоретический характер. Результаты опубликованных клинических исследований эффективности умифеновира при COVID-19 противоречивы. Решение о применении умифеновира при COVID-19 должно приниматься индивидуально, принимая во внимание «экспериментальный» характер подобного рода терапии.

At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical. The published clinical trials have contradicting results. The decision to use umifenovir in COVID-19 should be individualized, considering the “experimental” nature of this treatment.

коронавирусумифеновирCOVID-19coronavirusumifenovirCOVID-19ReferencesГосударственный реестр лекарственных средств. ЛСР-003900/07. [Электронный ресурс]. Доступно по: https://grls.rosminzdrav.ru/ Ссылка активна на 30.05.2020State register of medicines. ЛСР-003900/07. (In Russ). Доступно по: https://grls.rosminzdrav.ru/ Ссылка активна на 30.05.2020Fink SL, Vojtech L, Wagoner J et al. The Antiviral Drug Arbidol Inhibits Zika Virus. Sci Rep. 2018 Jun 12;8(1):8989. DOI: 10.1038/s41598-018-27224-4Fink SL, Vojtech L, Wagoner J et al. The Antiviral Drug Arbidol Inhibits Zika Virus. Sci Rep. 2018 Jun 12;8(1):8989. DOI: 10.1038/s41598-018-27224-4Hulseberg CE, Feneant L, Szymanska-de Wijs KM et al. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. J Virol. 2019 Apr 3;93(8): e02185-18. DOI: 10.1128/JVI.02185-18Hulseberg CE, Feneant L, Szymanska-de Wijs KM et al. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses. J Virol. 2019 Apr 3;93(8): e02185-18. DOI: 10.1128/JVI.02185-18Li MK, Liu YY, Wei F et al. Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo. Int J Antimicrob Agents. 2018 Jan;51(1):98-106. DOI: 10.1016/j.ijantimicag.2017.09.001Li MK, Liu YY, Wei F et al. Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo. Int J Antimicrob Agents. 2018 Jan;51(1):98-106. DOI: 10.1016/j.ijantimicag.2017.09.001Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014 Jul;107:84-94. DOI: 10.1016/j.antiviral.2014.04.006Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014 Jul;107:84-94. DOI: 10.1016/j.antiviral.2014.04.006Pecheur EI, Borisevich V, Halfmann P, et al. The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. J Virol. 2016 Jan 6;90(6):3086-92. DOI: 10.1128/JVI.02077-15Pecheur EI, Borisevich V, Halfmann P, et al. The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. J Virol. 2016 Jan 6;90(6):3086-92. DOI: 10.1128/JVI.02077-15ВРЕМЕННЫЕ МЕТОДИЧЕСКИЕ РЕКОМЕНДАЦИИ. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) 7-е изд., Москва: Министерство здравоохранения Российской Федерации, 2020. Доступно по: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf Ссылка активна на 30.05.2020THE PROVISIONAL GUIDELINES. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 7th ed., Moscow: Ministry of health of the Russian Federation, 2020 (In Russ). Доступно по: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf Ссылка активна на 30.05.2020Wright ZVF, Wu NC, Kadam RU, et al. Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. Bioorg Med Chem Lett. 2017;27(16):37443748. DOI: 10.1016/j.bmcl.2017.06.074Wright ZVF, Wu NC, Kadam RU, et al. Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. Bioorg Med Chem Lett. 2017;27(16):37443748. DOI: 10.1016/j.bmcl.2017.06.074Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020 May 2;6:28. DOI: 10.1038/s41421-020-0169-8Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020 May 2;6:28. DOI: 10.1038/s41421-020-0169-8Naveen V. Arbidol: A potential antiviral drug for the treatment of SARSCoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020 Aug;56(2):105998. DOI: 10.1016/j.ijantimicag.2020.105998Naveen V. Arbidol: A potential antiviral drug for the treatment of SARSCoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020 Aug;56(2):105998. DOI: 10.1016/j.ijantimicag.2020.105998Atanu Barik, Geeta Rai, Gyan Modi. Molecular docking and binding mode analysis of selected FDA approved drugs against COVID-19 selected key protein targets: An effort towards drug repurposing to identify the combination therapy to combat COVID-19. arXiv:2004.06447 [q-bio.BM] (or arXiv:2004.06447v1 [q-bio.BM] for this version)Atanu Barik, Geeta Rai, Gyan Modi. Molecular docking and binding mode analysis of selected FDA approved drugs against COVID-19 selected key protein targets: An effort towards drug repurposing to identify the combination therapy to combat COVID-19. arXiv:2004.06447 [q-bio.BM] (or arXiv:2004.06447v1 [q-bio.BM] for this version)Najim A. Al-Masoudi, Rita S. Elias, Bahjat Saeed. Molecular Docking Studies of some Antiviral and Antimalarial Drugs Via Bindings to 3CLProtease and Polymerase Enzymes of the Novel Coronavirus (SARSCoV-2). Biointerfaceresearch. 6444 2020;10(5):6444-6459. DOI: 10.33263/BRIAC105.64446459Najim A. Al-Masoudi, Rita S. Elias, Bahjat Saeed. Molecular Docking Studies of some Antiviral and Antimalarial Drugs Via Bindings to 3CLProtease and Polymerase Enzymes of the Novel Coronavirus (SARSCoV-2). Biointerfaceresearch. 6444 2020;10(5):6444-6459. DOI: 10.33263/BRIAC105.64446459Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. [Internet]. [cited 2020 March 3]; Available from: https://www.elotus.org/promo-files/COVID-19_resources/Guidance%20for%20Corona%20Virus%20Disease%202019%20(English%207th%20Edition%20Draft).pdfDiagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. [Internet]. [cited 2020 March 3]; Available from: https://www.elotus.org/promo-files/COVID-19_resources/Guidance%20for%20Corona%20Virus%20Disease%202019%20(English%207th%20Edition%20Draft).pdfCoronavirus Disease 2019 (COVID-19) Treatment Guidelines. [Internet]. [cited 2020 March 3]; Available from: https://www.covid19treatmentguidelines.nih.gov/Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. [Internet]. [cited 2020 March 3]; Available from: https://www.covid19treatmentguidelines.nih.gov/Nicastri E, Petrosillo N, Bartoli TA.National Institute for the Infectious Diseases «L. Spallanzani», IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543Nicastri E, Petrosillo N, Bartoli TA.National Institute for the Infectious Diseases «L. Spallanzani», IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543Clinical management of patients with COVID-19: Second interim guidance. [Internet]. [cited 2020 August 17]; Available from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirusinfection/clinical-management-covid-19.htmlClinical management of patients with COVID-19: Second interim guidance. [Internet]. [cited 2020 August 17]; Available from: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirusinfection/clinical-management-covid-19.htmlhttps://covid19evidence.net.au/https://covid19evidence.net.au/Clinical management of COVID-19. [Internet]. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19WHO/2019-nCoV/clinical/2020.5Clinical management of COVID-19. [Internet]. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19WHO/2019-nCoV/clinical/2020.5Zhu Z, Lu Z, Xu T et al. Arbidol monotherapy is superior to lopinavir/ ritonavir in treating COVID-19 [published online ahead of print, 2020 Apr 10]. J Infect. 2020 Jul;81(1):e21-e23. DOI: 10.1016/j.jinf.2020.03.060Zhu Z, Lu Z, Xu T et al. Arbidol monotherapy is superior to lopinavir/ ritonavir in treating COVID-19 [published online ahead of print, 2020 Apr 10]. J Infect. 2020 Jul;81(1):e21-e23. DOI: 10.1016/j.jinf.2020.03.060Chen W, Yao M, Fang Z et al. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19. J Med Virol. 2020 Jun 8;10.1002/jmv.26142. DOI: 10.1002/jmv.26142Chen W, Yao M, Fang Z et al. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19. J Med Virol. 2020 Jun 8;10.1002/jmv.26142. DOI: 10.1002/jmv.26142Deng L, Li C, Zeng Q et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort. J Infect. 2020 Jul;81(1):e1-e5. DOI: 10.1016/j.jinf.2020.03.002Deng L, Li C, Zeng Q et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort. J Infect. 2020 Jul;81(1):e1-e5. DOI: 10.1016/j.jinf.2020.03.002Lian N, Xie H, Lin S et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020 Jul;26(7):917-921. DOI: 10.1016/j.cmi.2020.04.026Lian N, Xie H, Lin S et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020 Jul;26(7):917-921. DOI: 10.1016/j.cmi.2020.04.026Liu Q, Fang X, Tian L et al. The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan. [Posted April 17, 2020]. Medrxiv. DOI: 10.1101/2020.04.11.20056523Liu Q, Fang X, Tian L et al. The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan. [Posted April 17, 2020]. Medrxiv. DOI: 10.1101/2020.04.11.20056523Zhang JN, Wang WJ, Peng B, et al. Potential of Arbidol for Postexposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study. Curr Med Sci. 2020 Jun;40(3):480-485. DOI: 10.1007/s11596-020-2203-3Zhang JN, Wang WJ, Peng B, et al. Potential of Arbidol for Postexposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study. Curr Med Sci. 2020 Jun;40(3):480-485. DOI: 10.1007/s11596-020-2203-3Реестр разрешений на проведение клинических исследований https://grls.rosminzdrav.ru/CiPermitionReg.aspxРеестр разрешений на проведение клинических исследований https://grls.rosminzdrav.ru/CiPermitionReg.aspxClinical trials for covid-19 and umifenovir. EU Clinical Trials Register. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19+and+umifenovirClinical trials for covid-19 and umifenovir. EU Clinical Trials Register. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=covid-19+and+umifenovirLiu X, Huang T, Chen JX et al. Arbidol exhibits strong inhibition towards UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Pharmazie. 2013 Dec;68(12):945-950.Liu X, Huang T, Chen JX et al. Arbidol exhibits strong inhibition towards UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Pharmazie. 2013 Dec;68(12):945-950.Dmitriev A, Filimonov D, Lagunin A et al. (2019). Prediction of severity of drug-drug interactions caused by enzyme inhibition and activation. Molecules. 2019 Oct 31;24(21):3955. DOI: 10.3390/molecules24213955Dmitriev A, Filimonov D, Lagunin A et al. (2019). Prediction of severity of drug-drug interactions caused by enzyme inhibition and activation. Molecules. 2019 Oct 31;24(21):3955. DOI: 10.3390/molecules24213955

The authors declare that there are no conflicts of interest present.